Harzklinikum Dorothea Christiane Erxleben GmbH — Clinical Trial Site

9 Registered trials

2 Currently recruiting

Organisation

Harzklinikum Dorothea Christiane Erxleben GmbH

Location

Quedlinburg, Germany

Identifier

ORG-100024657

Address

Ditfurter Weg 24, 06484, Germany

Departments

Dermatologie und Allergologie
Dermatology
Klinik für Dermatologie & Allergologie
Klinik für Dermatologie und Allergologie
Klinik für Dermatologie und Allergologie - Studienzentrum

Clinical trials at this site (9)

Search interface

Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou… Recruiting

2025-520771-59-00 Atopic Dermatitis 4 2026-02-03
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended

2024-515494-95-00 Moderate to Severe Atopic Dermatitis (AD) 4 2025-05-26
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica… Ended

2023-509394-23-00 Stage II melanoma arising from a primary cutaneous site 5 2020-06-12
A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended

2024-510913-13-00 Previously Untreated Metastatic or Unresectable Melanom 10 2018-05-18
Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidrade… Ended

2024-518180-35-00 Hidradenitis Suppurativa 4 2025-03-03
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Psoriasis 4 2023-03-15